Term ended May 2, 2025 · High confidence
20-year base term ended May 2, 2025
May 2, 2005
May 2, 2025
Aug 15, 2017
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. Confidence: High. from the record
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts May 2, 2005, when application 11/121,294, the earliest non-provisional in its chain, was filed (this one was filed Oct 9, 2015) | May 2, 2025 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 8,147,867, US 8,329,213, US 8,658,203, US 8,703,181, US 8,992,970, US 9,717,723, US 9,724,303, US 9,737,528, US 9,782,349) | resolves to May 2, 2025, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 2 maintenance fees paid | term ended | High confidence |
| Computed term end | The steps above, in order | May 2, 2025 | High confidence |
This family
| US 8,147,867 | In force Aug 2028 | Aug 2028 |
| US 8,658,203 | In force Nov 2029 | Nov 2029 |
| US 8,329,213 | In force Jan 2027 | Jan 2027 |
| US 8,703,181 | Term ended May 2025 | May 2025 |
| Application 14/151,632 | Abandoned not computed | not computed |
| US 8,992,970 | Term ended May 2025 | May 2025 |
| US 9,717,723 | Term ended May 2025 | May 2025 |
| US 9,730,891 | this patent May 2025 | May 2025 |
Assignments
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Dec 28, 2015 Reel 37394, frame 285 | Merrimack Pharmaceuticals, Inc. | U.S. Bank National Association, as Collateral Agent | Security Interest |
| Jan 4, 2016 Reel 37400, frame 786 | Hong, Keelung; Drummond, Daryl C.; Kirpotin, Dmitri | Hermes Biosciences, Inc. | Assignment of Assignor's Interest |
| Jan 4, 2016 Reel 37400, frame 836 | Hermes Biosciences, Inc. | Merrimack Pharmaceuticals, Inc. | Merger |
| Apr 14, 2017 Reel 42254, frame 349 | U.S. Bank National Association | Merrimack Pharmaceuticals, Inc. | Release of Security Interest |
| May 1, 2017 Reel 42377, frame 696 | Merrimack Pharmaceuticals, Inc. | Ipsen Biopharm Ltd. | Assignment of Assignor's Interest |
| May 17, 2017 Reel 42522, frame 334 | Merrimack Pharmaceuticals, Inc. | Ipsen Biopharm Ltd. | Change of Address of Assignee |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
A terminal disclaimer resolved from the filed document, referencing US 8,147,867, US 8,329,213, US 8,658,203, US 8,703,181, US 8,992,970, US 9,717,723, US 9,724,303, US 9,737,528, US 9,782,349, ends no earlier than this term, so it caps nothing.